- TM Capital served as financial advisor to DCN Dx in connection with a growth equity investment from Martis Capital
- DCN Dx is a leading provider of contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assays
- DCN Dx supports an array of customers including global diagnostics manufacturers, non-profits seeking tests for low-resource settings and start-ups launching diagnostic-based products
- Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers
- Martis Capital is a private equity firm which manages more than $1.2 billion of equity and is focused exclusively on investing in middle market growth companies in the healthcare industry
Life Sciences & Diagnostics,
Healthcare
|
Mergers & Acquisitions
